SecBot SecBot
SECBOTREPLAY Home › Report › TMDX

TMDX · TransMedics provided additional details on its Q4 2025 financial…

TransMedics Group, Inc. · 8-K filed Feb 27, 2026 at 08:25 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Feb 27, 2026 at 08:25 ET

TransMedics provided additional details on its Q4 2025 financial results, clarifying that the previously reported $105.4 million net income included a one-time $83.8 million tax benefit from releasing a $103.3 million U.S. valuation allowance. Adjusted net income for the quarter was $17.5 million. The company reaffirmed its expectation of future tax provisions aligning with statutory rates.

  • TransMedics released a $103.3 million U.S. tax valuation allowance in Q4 2025, resulting in an $83.8 million net income tax benefit.
  • Reported Q4 2025 net income was $105.4 million; adjusted net income, excluding the tax benefit, was $17.5 million.
  • The annual effective tax rate for 2025 was (77.0)%, but would have been 19.1% without the valuation allowance release.
  • The company expects future quarterly tax provisions to be in line with U.S. statutory corporate income tax rates.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access